Introduction to Biological and Small Molecule Drug Research and Development: theory and case studiesby C. Robin Ganellin
Introduction to Biological and Small Molecule Drug Research and Development provides, for the first time, an introduction to the science behind successful pharmaceutical research and development programs. The book explains basic principles, then compares and contrasts approaches to both biopharmaceuticals (proteins) and small molecule drugs, presenting an/i>… See more details below
Introduction to Biological and Small Molecule Drug Research and Development provides, for the first time, an introduction to the science behind successful pharmaceutical research and development programs. The book explains basic principles, then compares and contrasts approaches to both biopharmaceuticals (proteins) and small molecule drugs, presenting an overview of the business and management issues of these approaches. The latter part of the book provides carefully selected real-life case studies illustrating how the theory presented in the first part of the book is actually put into practice. Studies include Herceptin/T-DM1, erythropoietin (Epogen/Eprex/NeoRecormon), anti-HIV protease inhibitor Darunavir, and more.
Introduction to Biological and Small Molecule Drug Research and Development is intended for late-stage undergraduates or postgraduates studying chemistry (at the biology interface), biochemistry, medicine, pharmacy, medicine, or allied subjects. The book is also useful in a wide variety of science degree courses, in post-graduate taught material (Masters and PhD), and as basic background reading for scientists in the pharmaceutical industry.
- For the first time, the fundamental scientific principles of biopharmaceuticals and small molecule chemotherapeutics are discussed side-by-side at a basic level
- Edited by three senior scientists with over 100 years of experience in drug research who have compiled the best scientific comparison of small molecule and biopharmaceuticals approaches to new drugs
- Illustrated with key examples of important drugs that exemplify the basic principles of pharmaceutical drug research and development
Description: From the perspective of the world's leading experts in the field of drug discovery, this book is the first to bridge the fundamental principles of drug discovery gained from developing small molecules with the newer approaches of developing peptide/protein biopharmaceuticals as therapeutic entities. It first defines the very fundamental principles of drug discovery that are similar as well as those that are different with respect to development of small molecules versus development of large peptide/proteins as drugs.
Purpose: The editors have selected leading experts to articulate the basic principles of drug discovery required for the success of developing small-molecule therapeutic drugs versus developing large peptide/protein biopharmaceuticals as drugs. The two approaches have been compared from scientific and commercial perspectives culminating in a well-written and easy-to-read narrative on drug discovery. The editors have definitely achieved this goal.
Audience: This book is for every scientist who has an interest in drug discovery, from academicians to industrial scientists who are involved in developing, translating to clinical use, or marketing new drug entities.
Features: The first two chapters clearly articulate the fundamental chemical and biological principles that govern the interactions of small molecules with large molecule targets. The third chapter deals with the small-molecule drug discovery process, identifying key principles from target selection to drug candidate selection. The fourth chapter is an introduction to the field of biopharmaceuticals and defines the principles that have led to the development of several peptide/protein biopharmaceuticals as therapeutic agents, especially since 2005. The fifth chapter is a valuable discussion of the similarities and differences in the drug discovery process for small molecules versus large peptide/protein pharmaceuticals. Chapter 7 deals with the change in the business paradigm, including the management of risks and resources from the perspective of developing large peptide/protein biopharmaceuticals compared to the old paradigm of developing small molecules as drug entities. Finally, the science of drug discovery is illustrated with eight carefully selected real case studies describing how drug discovery translates into practice. The cases cover the discovery of therapies for the treatment of type 2 diabetes, inhibitors of the epidermal growth factor receptor tyrosine kinase to treat tumors, monoclonal antibodies to treat cancer, potential treatments for liposomal storage disorders, human erythropoietin analogs to treat anemias, anti-HIV protease inhibitors, anti-TNF agents to treat inflammatory disorders, and cholesterol absorption inhibitors to treat diabetes. Each of these case studies illustrates general concepts with specific examples. The clinical experience with the new drugs, both positive and negative, is discussed in detail for most of these cases.
Assessment: I highly recommend this book to anyone who has a role in the drug discovery process.
- Elsevier Science
- Publication date:
- Sold by:
- Barnes & Noble
- NOOK Book
- File size:
- 10 MB
and post it to your social network
Most Helpful Customer Reviews
See all customer reviews >